LOS ANGELES, June 22, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company
focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán,
Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on
June 22, 2016 at 9:00 am EDT in New York
City.
A webcast of this presentation will be available on Capricor's website at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery,
development and commercialization of first-in-class therapeutics. Capricor has two product candidates under clinical
investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a dual natriuretic peptide receptor agonist. CAP-1002 is in
development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy-associated
cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as other potential
indications. In addition, Capricor is evaluating its exosomes platform technology for cardiac diseases and other therapeutic
areas. For additional information, visit www.capricor.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product
candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings,
future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial
rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with
respect to the expected use of proceeds from the recently completed offering and the anticipated effects of the offering, and any
other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are
not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates,"
"expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements. More information about these and other risks that may impact
Capricor's business are set forth in Capricor's Annual Report on Form 10-K for the year ended December 31,
2015, as filed with the Securities and Exchange Commission on March 30, 2016, and in its
Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28,
2015 and in our Quarterly Report on Form 10-Q for the period ending March 31, 2016 as filed
with the Securities and Exchange Commission on May 13, 2016. All forward-looking statements in this
press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update
these forward-looking statements.
CAP-1002 and Cenderitide are Investigational New Drugs and are not approved for any indications.
For more information, please contact:
Corporate Contact:
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com
Investor Relations:
Argot Partners
Kimberly Minarovich
+1-212-600-1902
kimberly@argotpartners.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/capricor-therapeutics-to-present-at-jmp-life-sciences-conference-300288354.html
SOURCE Capricor Therapeutics, Inc.